Showing results (11-20 of 384) with videos related to
Sort By:
Pageof 39
BJU International|August 15, 2009
DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programmeSumit Isharwal, Danil V Makarov, H Ballentine Carter, et al.The Prostate|December 19, 2007
Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intentDanil V Makarov, Cameron Marlow, Jonathan I Epstein, et al.Future Oncology (London, England)|October 6, 2015
Regional variations in US cancer imaging data: a warning for imaging overuseDanil V Makarov, Gemma WestcottThe Journal of Urology|November 16, 2007
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomyDanil V Makarov, Elizabeth B Humphreys, Leslie A Mangold, et al.Urology|January 11, 2011
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance programSumit Isharwal, Danil V Makarov, Lori J Sokoll, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancerDanil V Makarov, Sumit Isharwal, Lori J Sokoll, et al.Urologic Oncology|December 2, 2006
Nucleic acid-based marker approaches to urologic cancersRobert W Veltri, Danil V MakarovThe Journal of Urology|November 7, 2006
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostateDanil V Makarov, H Ballentine CarterBJU International|September 30, 2010
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason scoreYing Huang, Sumit Isharwal, Alexander Haese, et al.International Journal of Radiation Oncology, Biology, Physics|July 3, 2010
A new formula for prostate cancer lymph node riskJames B Yu, Danil V Makarov, Cary GrossPageof 39